Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLGW) Share-based Compensation (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Share-based Compensation for 2 consecutive years, with $209626.0 as the latest value for Q4 2017.

  • Quarterly Share-based Compensation fell 82.6% to $209626.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Dec 2017, down 159.24% year-over-year, with the annual reading at $256358.0 for FY2025, 35.77% up from the prior year.
  • Share-based Compensation for Q4 2017 was $209626.0 at Bone Biologics, down from $367157.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $1.2 million in Q4 2016, with the low at -$3.5 million in Q2 2017.